T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research

项目概要 纳米技术与医学之间的结合是科学探索和科学探索的新领域 创建新的和改进的诊断和治疗工具来检测、治疗、治愈和预防 人类疾病。我们建议创建一个一体化的博士前和博士后培训计划 癌症研究纳米技术（NTCR）就位于这个界面。它基于两个父母 同一领域的 R25 和 T32 培训补助金。该计划将建立一个独特的国家资源 癌症生物学、工业基础研究的跨学科和协同项目 癌症医学领域的合作和转化研究。该计划培养博士前和 接受跨学科培训的博士后研究员为技术奠定基础 与目前有限的黑盒输入输出技术相比，癌细胞功能的内部视图 使用，引入分子成像的新模式，开发新的高通量诊断工具，以及 设计新型药物/抗体/siRNA 病毒和非病毒递送系统来治疗人类癌症。 NTCR 研究人员开发了新的癌症诊断方法来评估每个患者的预后和最佳状态 根据患者的遗传和表观遗传标记以及疾病表型进行治疗 为每个患者选择和优化的治疗方法。 NTCR 学员选三项之一 根据他们的背景提供核心课程，以及癌症纳米生物技术的实验课程。他们 参加期刊俱乐部和专门的年度研讨会，以及临床会议和肿瘤会议 板。 NTCR项目每年都会招募具有MD和/或PhD学位的优秀学员 以及生物化学、物理学、分子/细胞/癌症生物学或其他领域的不同背景 工程/物理学科稳定拥有 2 名博士后和 6 名博士前研究员。的 NTCR项目博士后培训期限为3年，博士前培训期限为4-5年。 NTCR 研究员利用 NCI 指定的 Sidney Kimmel 的研究和临床资源 综合癌症中心、路德威克癌症遗传学和治疗中心、The Sol 高盛胰腺癌中心、体内细胞和分子成像中心，以及 新成立的约翰·霍普金斯大学独特的教育资源和实验设施 纳米生物技术研究所 (INBT)，以前是癌症纳米技术中心 卓越中心 (CCNE) 和目前的物理科学肿瘤中心 (PSOC)。

Project Summary The interface between nanotechnology and medicine is a new frontier for scientific exploration and for the creation of new and improved diagnostic and therapeutic tools to detect, treat, cure, and prevent human diseases. We propose to create an integrated predoctoral and postdoctoral training program in nanotechnology for cancer research (NTCR) that is positioned at this interface. It is based on two parent R25 and T32 training grants in the same area. This program will establish a unique national resource with interdisciplinary and synergistic programs in fundamental research in cancer biology, industrial collaboration, and translational research in cancer medicine. This program fosters predoctoral and postdoctoral fellows who are trained across disciplines to lay foundations for technologies that enable an inside-view of cancer cell functions as opposed to the limited black-box input-output techniques currently used, introduce new modalities for molecular imaging, develop new high-throughput diagnostic tools, and engineer novel drug/antibody/siRNA viral and non-viral delivery systems to treat human cancers. NTCR fellows develop novel cancer diagnostics to evaluate each individual patient's prognosis and optimal treatment, based upon the patients' genetic and epigenetic markers and disease phenotype and therapeutics that are selected and optimized for each individual patient. NTCR trainees take one of three core courses depending on their background, as well as a lab course in cancer nanobiotechnology. They participate in a journal club and a dedicated annual symposium, as well as clinical conferences and tumor boards. The NTCR program will recruit outstanding trainees every year with MD and/or PhD degrees and diverse backgrounds in either biochemistry, physics, molecular/cellular/cancer biology, or an engineering/physics discipline for a steady state number of 2 postdoctoral and 6 predoctoral fellows. The NTCR program lasts 3 years for postdoctoral trainees and 4-5 years for predoctoral trainees. NTCR fellows take advantage of research and clinical resources at the NCI-designated Sidney Kimmel Comprehensive Cancer Center, the Ludwick Center for Cancer Genetics and Therapeutics, The Sol Goldman Pancreatic Cancer Center, and the In Vivo Cellular and Molecular Imaging Center, as well as the unique educational resources and experimental facilities of the recently established Johns Hopkins Institute for NanoBioTechnology (INBT), which previously housed the center for cancer nanotechnology excellence (CCNE) and currently the physical sciences-oncology center (PSOC).